

Updated safety & immunogenicity of 3rd dose CoronaVac[®]

Liming Wang, MD, PhD

Medical Manager of the Clinical Research Department, Sinovac

WHO R&D BLUEPRINT CONSULTATION MEETING

October 25, 2021




01


Safety of the 3rd dose of CoronaVac[®]

Safety profile within 28 days after the 3rd dose

18-59 years old (0,28d)+3rd dose at 6-8m after the 2nd dose



60 years old and above (0,28d) +3rd dose at 6-8m after the 2nd dose




Safety:

3rd dose of CoronaVac® after 6-8 months of primary immunization performed well in safety;

SINOVAC

AEFI did not increased after the 3rd dose



A 3rd dose after 6 months of 2-dose (0,28) vaccination, the incidence of adverse reactions (grade 2 or above) within 28 days



**Grade 2 was the highest level of adverse reactions for CoronaVac®
Grade 3 or above was not noticed.**

Pan HX, et al. "Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial" *medRxiv* (2021) Li M, et al. "A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial" *medRxiv* (2021)

Two doses of CoronaVac induced higher antibody response among previously Covid-19 infected HCWs




- Median Ig G titer: **1,220 AU/ml** (range: 202–10328 AU/mL) in previously infected HCWs vs **913 AU/ml** (range: 2.8–15547 AU/mL) in uninfected HCWs
- Seropositivity rate (≥ 50 AU/ml): 98% in all tested HCWs

02

Immunogenicity, timing, and immune persistence of the 3rd dose of CoronaVac[®]

Longer interval between 2nd and 3rd has a better immune response

GMT: 28 days after the 3rd dose



6-12 Months interval between 2nd - 3rd dose produce better immune response after 3rd dose

SINOVAC

| | | | | |
|---------------------|------------------------------------|-------|-------|--------|
| Participants | 18-59 years old | | | |
| Schedule | Day 0, Day 28, Day 28+Mon 3/6/9/12 | | | |
| Sample size | Mon-3 | Mon-6 | Mon-9 | Mon-12 |
| | 100 | 100 | 100 | 100 |
| | 400 | | | |




Vaccination



Blood collection


GMT of the third dose with different interval




When the interval time is 6/9/12-mon between the second dose and the third dose, the GMT to the variants is higher than that of 3-mon.

Good immune persistence at 6 months after the 3rd dose

GMT: 6m after 3rd dose higher than the peak of 2 doses



Seropositivity remained high 6m after 3rd dose



- ▶ Homologous vaccine with a 3rd dose of CoronaVac® is safe
- ▶ Effective in recalling a SARS-CoV-2 specific immune response if given 6-8m after the 2nd dose
- ▶ China is scaling up the 3rd dose inactivated vaccination campaign
- ▶ More data are needed on cell immunity, effectiveness evaluation for the 3rd dose etc.
- ▶ Heterologous vaccine is under research

SINOVAC

Supply Vaccines to Eliminate Human Diseases



sinovac.com

Thank you!

SINOVAC : Supply Vaccines to Eliminate Human Diseases

科兴控股生物技术有限公司
SINOVAC BIOTECH LTD.